Bayer (which owns Monsanto) agreed to a $7.25 billion settlement in 2026 covering current and future non-Hodgkin lymphoma claims. If you used Roundup and were later diagnosed, you may still be able to file. We never sell your information.
The World Health Organization's cancer agency classified glyphosate, Roundup's active ingredient, as probably carcinogenic to humans in 2015. Tens of thousands of people who used Roundup at work or in their yards were later diagnosed with non-Hodgkin lymphoma. The federal cases are consolidated as MDL 2741 before Judge Vince Chhabria in the Northern District of California. In 2026 Bayer agreed to a $7.25 billion settlement resolving current and future claims.
The link is specific. In 2015 the International Agency for Research on Cancer (IARC), the WHO's cancer arm, reviewed the evidence and classified glyphosate as probably carcinogenic to humans. Multiple later analyses associated heavy glyphosate exposure with a higher rate of non-Hodgkin lymphoma.
The people most affected used Roundup the most: farmers, landscapers, groundskeepers, nursery and agricultural workers, and homeowners who sprayed it season after season. The federal MDL 2741 is consolidated before Judge Vince Chhabria in the Northern District of California; Bayer's 2026 settlement is structured to cover people diagnosed now and in the future.
The documented basis for these claims:
Non-Hodgkin lymphoma is the core diagnosis; several NHL subtypes and related blood cancers are also named.
The central diagnosis in the Roundup litigation, including subtypes such as diffuse large B-cell lymphoma and follicular lymphoma.
Tied to relaxer use: IARC's 2015 review specifically noted an association between glyphosate exposure and non-Hodgkin lymphoma.
A slow-growing blood cancer considered a subtype of NHL and accepted in many Roundup intakes.
Tied to relaxer use: CLL is classified under the NHL umbrella by the WHO.
A cancer of plasma cells named in some Roundup filings based on epidemiological associations.
Tied to relaxer use: Some studies of agricultural workers reported elevated multiple myeloma rates with glyphosate exposure.
The 60-second check above tells you if your situation fits the settlement criteria. Free, confidential, no obligation.
Four steps. After the first one, the attorney's team does almost everything.
Three questions confirm the basics: glyphosate exposure, diagnosis, and attorney status.
About 60 seconds.An attorney from the network reviews your answers and follows up to confirm whether your situation fits the settlement's intake criteria.
1 to 2 business days.If accepted, the intake team collects your pathology, treatment, and exposure history. You sign a release; they handle the rest.
3 to 6 weeks.Once records are complete, your claim is submitted. Your attorney handles the process through resolution. You can withdraw before signing a representation agreement.
Filing within 30 days of records being complete.Every state sets a deadline (statute of limitations) to file. Once it runs out, the right to file is gone. Because a settlement is now in place, intake windows and claim deadlines can move quickly.
If you are unsure whether you are still within the window, run the check now. The attorney review is free and the deadline question is one of the first things they evaluate.
claimscout is not a law firm. We connect you with attorneys from a vetted network of firms that handle Roundup (MDL 2741) claims.
claimscout is a referral service. We do not provide legal advice and are not a substitute for an attorney-client relationship. Sponsored attorney advertising. Past results do not guarantee future outcomes.
You do not need to prove the science on Roundup. The science is already litigated and Bayer has agreed to pay. Your job is simply to confirm you used the product and were diagnosed.
Non-Hodgkin lymphoma is the primary diagnosis, including subtypes like diffuse large B-cell and follicular lymphoma. Chronic lymphocytic leukemia (CLL) and, in some intakes, multiple myeloma are also considered.
Yes. Bayer's 2026 settlement is structured to cover both current and future non-Hodgkin lymphoma claims, so people who used Roundup and were diagnosed can still pursue a claim. Deadlines apply, which is why checking now matters.
It can. Both occupational users (farmers, landscapers, groundskeepers) and residential users who sprayed regularly over the years are represented in the litigation.
Reported individual payouts range roughly from $6,000 to $165,000, driven by exposure length, diagnosis severity, and treatment history. Your attorney gives a case-specific estimate after reviewing your records.
Most claimants document use through a sworn declaration covering product, years of use, and setting (job or home). Receipts help but are not required.
We connect you. The check routes qualified cases to a Roundup-experienced attorney from the network, and you can accept or decline.
Nothing. We get paid by the law firms or affiliate fees from the court-appointed administrator. You pay zero up front and zero out of any payout you receive.
Only if you check the consent box. We give you the choice. If you do not consent, your claim is captured and we route it to the administrator directly without sharing your phone number.
Yes, always. If we route your claim to a law firm, you can choose to file directly with the same firm or pick a different one. We exist because most people throw the notice letter away. We make it not happen.
No. We are not a law firm and do not provide legal advice. We are a platform that captures your claim, qualifies it, and routes it to the court-appointed administrator or a law firm of your choice.